Abstract
Background:
Since for pancreatic cancer the mortality rate approaches the incidence rate with only 1-4% of all patients surviving 5 years, it would be would be of great value to provide chemopreventive treatment for high-risk individuals.
Discussion:
The preclinical study of pancreatic intraepithelial neoplasia (PanINs) has recently been made possible by the generation of genetically modified animal models, which recapitulate human PanINs and invasive pancreatic cancer on a genetic and histomorphologic level. Very recently, several groups have reported first evidence of chemoprevention of pancreatic cancer.
MeSH terms
-
Animals
-
Animals, Genetically Modified
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Biomedical Research
-
Carcinoma in Situ / genetics
-
Carcinoma in Situ / mortality
-
Carcinoma in Situ / prevention & control*
-
Carcinoma, Pancreatic Ductal / genetics
-
Carcinoma, Pancreatic Ductal / mortality
-
Carcinoma, Pancreatic Ductal / prevention & control*
-
Cell Line, Tumor
-
Cell Transformation, Neoplastic / drug effects
-
Cell Transformation, Neoplastic / genetics
-
Cell Transformation, Neoplastic / pathology
-
Disease Models, Animal
-
Humans
-
Mice
-
Neoplasm Invasiveness
-
Neoplasm Transplantation
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / mortality
-
Pancreatic Neoplasms / prevention & control*
-
Risk Factors
-
Survival Rate